| Field | Specification |
|---|---|
| Target | |
| Alternative names | NFX-179 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C17H16FIN4O3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Nedometinib (NFX-179) is a specific MEK1 inhibitor, with an IC50 of 135 nM. It inhibits p-ERK and MAPK, exerts anticancer activity against squamous cell carcinoma, and can be used for research in dermatosis and neurofibromatosis[1][2]. It is supplied as an off-white to light yellow solid (C17H16FIN4O3, MW 470.24) at 98.09% purity.
Physical & Chemical Properties
| CAS Number | 2252314-46-6 |
|---|---|
| Molecular Formula | C17H16FIN4O3 |
| Molecular Weight | 470.24 g/mol |
| Purity | 98.09% |
| Appearance | Solid |
| Color | Off-white to light yellow |
| SMILES | O=C(C1=C(NC2=CC=C(C=C2F)I)N(C)C3=C1C=CC=N3)NOCCO |
| Target | MEK1 |
| Signaling Pathway | MAPK/ERK Pathway; Cell Cycle/DNA Damage |
| Solubility | In Vitro: DMSO: 100 mg/mL (212.66 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, protect from light, stored under nitrogen. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[2]
|
MEK1 135 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Kincaid, et al. Preparation of pyrrolopyridine-aniline compounds for treatment of dermal disorders. World Intellectual Property Organization, WO2018213810 A1. 2018-11-22.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (212.66 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light, stored under nitrogen; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
NFX-179 is cytotoxic to the A375 (BRAF-mutant) and HCT116 (KRAS-mutant) cell lines[2]. NFX-179 (0.01-30 μM; 72 h) reduces viability in a dose-dependent manner in the human SCC cell lines IC1, SRB1, SRB12, and COLO16, where IC50 values are 27 nM, 420 nM, 228 nM, and 91 nM in that order[2].
In Vivo
In an ultraviolet-induced mouse model of cSCC, topical NFX-179 (0.1%-2.3%; once a day; 30 days) suppresses cSCC formation. In minipigs, topical NFX-179 gel (0.01%-0.5%; 28 days) gives higher drug concentrations in the skin than in the plasma and inhibits MAPK signaling pathway activity in the skin.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Celastrol synergizes with MEK1 inhibitor nedometinib to overcome resistance in bladder cancer via dual suppression of CDK1/CDC5L and feedback-activated Akt/STAT3. Biochem Pharmacol 2026 Mar:245:117629. PMID: 41386559
